IRD (Opus Genetics) Dividends per Share : $0.00 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Dividends per Share?

Opus Genetics's dividends per share for the three months ended in Dec. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Opus Genetics's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Opus Genetics Dividends per Share Historical Data

The historical data trend for Opus Genetics's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Dividends per Share Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Opus Genetics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Opus Genetics's Dividends per Share

For the Biotechnology subindustry, Opus Genetics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opus Genetics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Opus Genetics Dividends per Share Calculation

Dividends paid to per common share.

Opus Genetics (NAS:IRD) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Opus Genetics's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-1.27
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Opus Genetics Dividends per Share Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Opus Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (NAS:IRD) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

R3X1:Germany

Address

8 Davis Drive, Suite 220, Durham, NC, USA, 27709

Website

https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Executives

George Magrath	officer: Chief Executive Officer	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel	officer: SVP, Operations & Bus. Dev.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch	director, officer: President and CEO	17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J	director	5130 ROUTE 212, WILLOW NY 12495
Jay Pepose	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton	director	3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba	officer: VP of Finance	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher	director	6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer	director
Sean Ainsworth	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann	officer: VP of Corp. Dev. & Ops & Sec.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price	director	8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky	officer: President and CFO	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732